At Opticyte, we are committed to transforming the standard of care for the leading causes of organ failure, including sepsis. The problem is massive, is expensive to treat, and leads to one death every 2.8 seconds globally. Current technologies including pulse oximeters fail to provide clinicians with the definitive data they need to diagnose, monitor, and treat patients in real-time, when they have the best chance of preventing organ failure.
Opticyte's Cell O2 Monitor is the first and only single solution to provide definitive, continuous, and actionable insights for this critical unmet need. Opticyte's executive and advisory team includes pioneers in new optical spectroscopy and multivariate analysis technology, leaders in medical device commercialization, and medical clinicians. The company’s early funding successes, research validation, and product development milestones provide credibility and reinforce our position as a disruptive medical device innovator.
Location: United States, Washington, Seattle
Employees: 1-10
Total raised: $4.6M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Puget Soun... | pugetsound... |
| - | Swan Ventu... | swanventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.01.2021 | - | $4.6M | - |
Mentions in press and media 2
| Date | Title | Description |
| 12.01.2021 | Opticyte Secures $4.6 Million in Funding to Develop First Cell O2 Monitor for Reducing Organ Failure | Opticyte obtains funding from a $2.9MM SBIR Phase IIB grant and completes a $1.7MM seed round to launch first observational trial of Opticyte Cell O2 Monitor Opticyte, Inc, a medical device innovator developing proprietary advanced algorith... |
| 11.01.2021 | UW spinout Opticyte lands $4.6M to test device that quickly detects early signs of organ failure | Lori Arakaki, Opticyte co-founder and CEO. (Opticyte Photo) University of Washington biotech spinout Opticyte has landed $2.9 million in federal grants and $1.7 million in seed funding. The Seattle startup is developing a non-invasive techn... |